Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Archive ouverte

Tam, C. S. | Kapoor, P. | Castillo, J. J. | Buske, C. | Ansell, S. M. | Branagan, A. R. | Kimby, E. | Li, Y. | Palomba, M. L. | Qiu, L. | Shadman, M. | Abeykoon, J. P. | Sarosiek, S. | Vos, J. | Yi, S. | Stephens, D. | Roos-Weil, D. | Roccaro, A. M. | Morel, Pierre | Munshi, N. C. | Anderson, K. C. | San-Miguel, J. | Garcia-Sanz, R. | Dimopoulos, M. A. | Treon, S. P. | Kersten, M. J.

Edité par CCSD -

International audience. Recent advances in the understanding of Waldenström macroglobulinemia (WM) biology have impacted the development of effective novel agents and improved our knowledge of how the genomic background of WM may influence selection of therapy. Consensus Panel 7 (CP7) of the 11th International Workshop on WM was convened to examine the current generation of completed and ongoing clinical trials involving novel agents, consider updated data on WM genomics, and make recommendations on the design and prioritization of future clinical trials. CP7 considers limited duration and novel-novel agent combinations to be the priority for the next generation of clinical trials. Evaluation of MYD88, CXCR4 and TP53 at baseline in the context of clinical trials is crucial. The common chemoimmunotherapy backbones, bendamustine-rituximab (BR) and dexamethasone, rituximab and cyclophosphamide (DRC), may be considered standard-of-care for the frontline comparative studies. Key unanswered questions include the definition of frailty in WM; the importance of attaining a very good partial response or better (≥VGPR), within stipulated time frame, in determining survival outcomes; and the optimal treatment of WM populations with special needs

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion